RecruitingNCT05392881
Interstitial Lung Disease Research Unit Biobank
University of Kansas Medical Center Interstitial Lung Disease Research Unit (ILDRU) Biobank
Sponsor
University of Kansas Medical Center
Enrollment
1,000 participants
Start Date
Aug 9, 2021
Study Type
OBSERVATIONAL
Conditions
Summary
Establish a interstitial lung disease (ILD) registry and biorepository to lead towards a further understanding of the disease.
Eligibility
Min Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a new treatment for people with hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05392881
Related Trials
Fibrotic Disease Activity in Cardiopulmonary Disorders Using 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) PET/CT Imaging
NCT076130991 location
A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard Treatment
NCT0703652346 locations
A Study to Find an Efficacious and Safe Dose of CHF10067 (Zampilimab) in Participants With Idiopathic Pulmonary Fibrosis
NCT075169511 location
A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Disease
NCT073237327 locations
Pulmonary Fibrosis Foundation Community Registry
NCT053825721 location